Remove 2017 Remove Research Remove Treatment
article thumbnail

Biotech leader champions targeted cancer treatments and diversity

Drug Target Review

As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted small molecules aimed at revolutionising cancer treatment. I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development.

article thumbnail

Vamorolone

New Drug Approvals

Vamorolone , sold under the brand name Agamree , is a synthetic corticosteroid , which is used for the treatment of Duchenne muscular dystrophy. [4] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age. Treatment of crude 9.3 4] [5] [6] [7] [8] It is taken by mouth. [1] with peracetic acid 9.4

FDA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Forging a Path Forward for Substance Abuse Potential Studies With the Cross-Company Abuse Liability Council By Beatrice Setnik, PhD

Alta Sciences

Addressing New Challenges in Human Abuse Potential Research The CCALC has held face-to-face meetings in collaboration with industry, academia, and the FDA once every two to three years since inception, and has provided much of the industry perspective on the practical challenges and solutions to assessing abuse and dependence potential.

article thumbnail

In vivo CAR T: Faster, cheaper, and more effective cancer care

Drug Target Review

Since their first approvals in 2017, autologous CAR T-cell therapies have revolutionised the treatment of blood cancers, offering hope where previous options had failed. Treatment outcomes for large B-cell lymphoma were dismal before CAR T-cell therapies.

article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

The Merkin Prize recognizes novel technologies that have improved human health and is administered by the Broad Institute, one of the worlds leading biomedical research institutes. The work of June, Levine, Rivire, and Sadelain laid the foundation for a whole new class of treatments.

article thumbnail

The Role of the FDA’s Oncology Center of Excellence in Advancing Cancer Care

The Premier Consulting Blog

Established in 2017 under the 21st Century Cures Act, the OCE brings together multidisciplinary scientific expertise to accelerate the review and approval of drugs, biologics, and medical devices for cancer care.

article thumbnail

A Visual Guide to Genome Editors

Codon

.” Four years earlier, in 2019, Gray had become the first patient with sickle cell anemia — a genetic disorder that causes red blood cells to become sticky and rigid — to receive an experimental treatment using CRISPR genome editing. Researchers have since discovered variants of the protein with additional useful qualities.

DNA